NDRA ENDRA Life Sciences Quick Ratio

The price trajectory of ENDRA Life Sciences (NDRA) demonstrates dynamics where the quick ratio is 7.29. The biopharmaceutical sector relies on steady demand, although sanctions and geopolitics may disrupt raw material logistics. ENDRA Life Sciences generates revenue through the sale of patented TAEUS systems for affordable ultrasound analysis of liver fat. Intellectual property protection and FDA requirements create barriers for competitors until the stage of full commercialization.

For ENDRA Life Sciences (NDRA), the creator of the high-precision TAEUS liver diagnostic system, this indicator assesses the ability to cover short-term debts without relying on inventory. The metric measures only available cash flow and accounts receivable, excluding illiquid assets. By analyzing the acid-test ratio trend, an investor gains a real-time assessment of the company's actual solvency. An excess of such resources may indicate inefficient capital management.